20:31 , Jan 18, 2019 |  BC Week In Review  |  Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
23:28 , Jan 17, 2019 |  BC Extra  |  Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

Poteligeo mogamulizumab: Preliminary Phase II data

Preliminary data from an open-label, international Phase II trial in 71 patients with relapsed or refractory ATL showed that 1 mg/kg Poteligeo every week for 4 weeks followed by every other week led to a...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Spectrum Pharmaceuticals, Servier deal

Spectrum granted Servier’s Servier Canada Inc. affiliate exclusive, Canadian rights to develop and commercialize four cancer drugs. The deal covers Zevalin ibritumomab for follicular B cell non-Hodgkin’s lymphoma (NHL); Fotolyn pralatrexate and Beleodaq belinostat for...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Alisertib: Phase III data

The open-label, international Phase III Lumiere trial in 163 evaluable patients with relapsed or refractory PTCL showed that twice-daily 50 mg oral alisertib for the first 7 days of a 21-day cycle led to an...
07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

Alisertib: Development discontinued

Takeda discontinued development of alisertib to treat relapsed or refractory PTCL after a pre-specified interim analysis of an open-label, international Phase III trial showed that twice-daily oral alisertib for the first 7 days of a...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Beleodaq belinostat regulatory update

FDA granted accelerated approval to Beleodaq belinostat from Spectrum to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). The approval came more than a month ahead of the Aug. 9 PDUFA date. Spectrum plans to...
22:35 , Jul 3, 2014 |  BC Extra  |  Company News

FDA approves Spectrum's belinostat

FDA granted accelerated approval to Beleodaq belinostat from Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). The approval came nearly a month ahead of the Aug. 9 PDUFA date. Spectrum...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Clinical News

Belinostat: Final Phase II data

Final data from the open-label, international, pivotal Phase II BELIEF (PXD101-CLN-19) trial in 129 patients with relapsed or refractory PTCL showed that once-daily IV belinostat led to an ORR of 26%, including a 10% complete...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Belinostat: Additional Phase II data

Topotarget reported additional data from the open-label, international, pivotal Phase II BELIEF (PXD101-CLN-19) trial in 129 patients with relapsed or refractory PTCL showing that once-daily IV belinostat led to an ORR that is "on par"...